WO2015136551A3 - A molecular complex of epigallocatechin-3-gallate and a process for production thereof - Google Patents

A molecular complex of epigallocatechin-3-gallate and a process for production thereof Download PDF

Info

Publication number
WO2015136551A3
WO2015136551A3 PCT/IN2015/000122 IN2015000122W WO2015136551A3 WO 2015136551 A3 WO2015136551 A3 WO 2015136551A3 IN 2015000122 W IN2015000122 W IN 2015000122W WO 2015136551 A3 WO2015136551 A3 WO 2015136551A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecular complex
gallate
epigallocatechin
production
fructo
Prior art date
Application number
PCT/IN2015/000122
Other languages
French (fr)
Other versions
WO2015136551A2 (en
Inventor
Saikat Roy
Anil Kumar
Jose DAVID
Bhargav MESHIYA
Ravindra BARHALIKAR
Silpi DATTA
Original Assignee
Tata Chemicals Limited
Tata Global Beverages Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tata Chemicals Limited, Tata Global Beverages Limited filed Critical Tata Chemicals Limited
Publication of WO2015136551A2 publication Critical patent/WO2015136551A2/en
Publication of WO2015136551A3 publication Critical patent/WO2015136551A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A molecular complex of Epigallocatechin-3-gallate is disclosed. The molecular complex comprises Epigallocatechin-3-gallate and a molecular complex former selected from Trehalose, Sucralose, Glutamic Acid, Glutamine, Glycine, Lipoic Acid, Carnosine, Maltose, Maltitol, Fructo-oligosaccharides and mixture thereof.
PCT/IN2015/000122 2014-03-12 2015-03-11 A molecular complex of epigallocatechin-3-gallate and a process for production thereof WO2015136551A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN825/MUM/2014 2014-03-12
IN825MU2014 2014-03-12

Publications (2)

Publication Number Publication Date
WO2015136551A2 WO2015136551A2 (en) 2015-09-17
WO2015136551A3 true WO2015136551A3 (en) 2016-01-14

Family

ID=54072546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000122 WO2015136551A2 (en) 2014-03-12 2015-03-11 A molecular complex of epigallocatechin-3-gallate and a process for production thereof

Country Status (1)

Country Link
WO (1) WO2015136551A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049688B (en) * 2016-12-15 2023-01-03 国际香料和香精公司 Novel compositions for taste masking
EP3488849A1 (en) * 2017-11-23 2019-05-29 Assistance Publique, Hopitaux De Paris Epigallocathechin gallate solution

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
WO2003011339A1 (en) * 2001-07-30 2003-02-13 Dsm Ip Assets B.V. Composition for epigallocatechin gallate
WO2008153938A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Epigallocatechin-3-gallate crystal compositions
WO2010025335A2 (en) * 2008-08-29 2010-03-04 Dr Pepper/Seven Up, Inc. Functional consumable compositions for promoting skin health and methods for using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
WO2003011339A1 (en) * 2001-07-30 2003-02-13 Dsm Ip Assets B.V. Composition for epigallocatechin gallate
WO2008153938A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Epigallocatechin-3-gallate crystal compositions
WO2010025335A2 (en) * 2008-08-29 2010-03-04 Dr Pepper/Seven Up, Inc. Functional consumable compositions for promoting skin health and methods for using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULES 2013, vol. 18, 4 January 2013 (2013-01-04), pages 574 - 587, ISSN: 1420-3049 *
SAKAGAMI ET AL.: "Alternative Medicine", FUNCTIONAL EVALUATION OF SASA MAKINO ET SHIBATA LEAF EXTRACT AS GROUP III OTC DRUG, 2012 *

Also Published As

Publication number Publication date
WO2015136551A2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
EP3283470A4 (en) Processes for producing 2,5-furandicarboxylic acid and derivatives thereof and polymers made therefrom
EP3356595A4 (en) Processes for producing nanocellulose, and nanocellulose compositions produced therefrom
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
SG10201502131QA (en) MEMBRANE COMPRISING SELF-ASSEMBLED BLOCK COPOLYMER AND PROCESS FOR PRODUCING THE SAME BY SPRAY COATING (IIc)
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3662033A4 (en) Amidoamine synthesis, methods to track the reaction process
MX2017011655A (en) Aza-pyridone compounds and uses thereof.
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
EP3572095A4 (en) Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
EP3094399B8 (en) Novel compounds for the capture of carbon dioxide from gaseous mixtures and subsequent release.
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
IN2013MU01985A (en)
MX2016017124A (en) Process for the preparation of 3-hydroxypicolinic acids.
MX2016015465A (en) Oral pharmaceutical composition of isotretinoin.
WO2015127284A3 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
WO2019109067A3 (en) Creatine prodrugs, compositions and methods of use thereof
EP3286373A4 (en) Methods for the production of high solids nanocellulose
WO2015136551A3 (en) A molecular complex of epigallocatechin-3-gallate and a process for production thereof
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2016027283A3 (en) A process for preparing indacaterol and salts thereof
WO2015095659A3 (en) Indirubin solid dispersion composition
EP3548457A4 (en) An improved process for the preparation of 2,3,3,3-tetrafluoropropene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15762172

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15762172

Country of ref document: EP

Kind code of ref document: A2